Skip to Main Content

Research

Conducting cutting-edge research to improve the care of people with diabetes is central to the mission of the Yale Children’s Diabetes Program. We rely on our patients as partners to join us on this mission. Without volunteers, even the most important studies will never be completed. Remember that all of our research studies are conducted with the utmost regard for safety, and as such are monitored and regulated by the Human Subjects Research Program at Yale, the Office for Human Research Protection at the US Department of Health and Human Services, the US Food and Drug Administration, and our research sponsors, such as the National Institutes of Health and Juvenile Diabetes Research Foundation. Our research participants often tell us that volunteering in studies has been helpful for their own diabetes care, as they often get to work very closely with the doctors, nurses, and other staff of the research team on an individual level.

Some major areas of research in our program are:

  • The Artificial Pancreas – We are evaluating the safety and effectiveness of devices that automatically link insulin pumps and glucose sensors and automatically regulate the blood glucose levels into a near-normal range. We were the first group to study these so-called “closed-loop” systems in children and are working closely with the NIH, JDRF, FDA, device manufacturers and other researchers to make this dream a reality.
  • Insulin Absorption – One of the key differences between people with diabetes versus those without diabetes is how the insulin is delivered into the body. When insulin is injected under the skin, whether by pump, syringe, or pen, it just takes longer to get to where it needs to in the body compared to how the normal pancreas works. We are working on several exciting strategies to speed up the action of insulin in the body. This has the potential to significantly improve the effectiveness of the artificial pancreas, and also the usual day-to-day management of diabetes people are doing now.
  • The Honeymoon Period – We know that some people with diabetes continue to make insulin years after the diagnosis of diabetes. We also know that people who continue to make insulin tend to do better with their diabetes: lower A1c levels, less hypoglycemia, fewer complications. We are working with other researchers on understanding how the functions of the pancreas change over the first years of diabetes, and on strategies to prolong the survival and function of those remaining beta cells.
  • Adjustment and Coping – We know that managing diabetes can be very stressful for the whole family: the child with diabetes, their siblings, and parents and other caregivers. It is important for you and for us to develop better tools to help monitor the levels of stress and coping in our families, and to provide strategies to improve and maintain a healthy quality of life.
  • Diabetes Standards of Care – We are partnering with many other diabetes centers across the country to pool our information about our practices: how well our patients are doing with diabetes; how often problems with hypoglycemia, ketoacidosis, or other problems develop; the use of technologies such as pumps and sensors; and how economic, social, and other factors affect diabetes care. This incredibly valuable information may help enable us to influence or direct healthcare policies to improve reimbursements and treatments for diabetes

Current Research

Check out the studies at Yale that are currently recruiting!

Less than 8 years old

There are no current ongoing studies in this age range that are recruiting participants.

Age 8- 17 years

There are no current ongoing studies in this age range that are recruiting participants.

Adult age 18+

There are no current ongoing studies in this age range that are recruiting participants.

New Diagnosis

TOPPLE T1D

A multiple ascending dose trial investigating safety, tolerability and pharmacokinetics of NNC0361-0041 administered subcutaneously to patients with type 1 diabetes mellitus (HIC#2000029217)

Type 1 Diabetes TrialNet is currently recruiting adults diagnosed with type 1 diabetes in the past 48 months for a Phase I clinical study testing the safety of a new plasmid therapy (NNC0361-0041).

Ages: 18-45

More information: www.trialnet.org

Contact: Lori Carria at lori.carria@yale.edu


PROTECT

Sponsored by Provention Bio, The PROTECT Study is testing how well an investigational medicine, called teplizumab, works in children and adolescents with Type 1 diabetes (T1D). your child is 8–17 years old and has recently been diagnosed with T1D he or she may be able to take part. Other medical criteria must be met before you can join the study, which will be assessed by the study team.

Ages: 8-17

Contact: Michele Alguard michele.alguard@yale.edu



Join TrialNet

https://www.trialnet.org/participate TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. They offer risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression.

Watch video

Prevention and Family

These studies target people with relatives with Type 1 Diabetes or people who have been identified as being at risk for Type 1 Diabetes.


The Natural History Study of the Development of Type 1 Diabetes: Pathway to Prevention FOR FAMILY MEMBERS ONLY

(HIC # 0608001761)

The goal of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals and is the first step in determining eligibility for prevention trials.

Ages: If you are 1-45 years of age AND have a brother, sister, child or parent with type 1 diabetes OR you are 1-20 years of age AND have a cousin, aunt, uncle, niece, nephew, half-sibling or grandparent with type 1 diabetes.

More information: Natural History Study

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu


HYDROXYCHLOROQUINE (HCQ) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS (HIC# 2000023905)

TrialNet investigators are testing a medication, called Hydroxychloroquine, to see if this treatment will delay or prevent the onset of abnormal glucose tolerance and type 1 diabetes in family members identified to be at risk for the disease. Participants in this study are screened in the Natural History/Pathway to Prevention Study.

Ages: at least 3 years old

More information: www.trialnet.org

Contact: Lori Carria at lori.carria@yale.edu